Fidelity Investments’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.84M | Sell |
368,429
-431,314
| -54% | -$3.2M | ﹤0.01% | 2522 |
|
|
2026
Q1 | $4.92M | Sell |
799,743
-567,246
| -41% | -$4.04M | ﹤0.01% | 2313 |
|
|
2025
Q4 | $9.86M | Sell |
1,366,989
-788,794
| -37% | -$6.38M | ﹤0.01% | 2036 |
|
|
2025
Q3 | $22M | Sell |
2,155,783
-178,341
| -8% | -$2M | ﹤0.01% | 1724 |
|
|
2025
Q2 | $24.3M | Sell |
2,334,124
-5,793
| -0.2% | -$61.7K | ﹤0.01% | 1632 |
|
|
2025
Q1 | $30.8M | Sell |
2,339,917
-83,296
| -3% | -$1.49M | ﹤0.01% | 1542 |
|
|
2024
Q4 | $43.4M | Sell |
2,423,213
-428,617
| -15% | -$8.68M | ﹤0.01% | 1436 |
|
|
2024
Q3 | $46M | Buy |
2,851,830
+2,341,054
| +458% | +$36.6M | ﹤0.01% | 1419 |
|
|
2024
Q2 | $13.8M | Buy |
510,776
+31,807
| +7% | +$759K | ﹤0.01% | 1778 |
|
|
2024
Q1 | $9.34M | Buy |
478,969
+221,354
| +86% | +$4.69M | ﹤0.01% | 1886 |
|
|
2023
Q4 | $5.33M | Buy |
257,615
+172,002
| +201% | +$5.13M | ﹤0.01% | 2044 |
|
|
2023
Q3 | $2.72M | Buy |
85,613
+235
| +0.3% | +$7.85K | ﹤0.01% | 2198 |
|
|
2023
Q2 | $2.87M | Buy |
85,378
+61,943
| +264% | +$2.22M | ﹤0.01% | 2216 |
|
|
2023
Q1 | $977K | Buy |
23,435
+5,582
| +31% | +$262K | ﹤0.01% | 2532 |
|
|
2022
Q4 | $605K | Sell |
17,853
-21,231
| -54% | -$903K | ﹤0.01% | 2660 |
|
|
2022
Q3 | $1.92M | Sell |
39,084
-32
| -0.1% | -$1.76K | ﹤0.01% | 2437 |
|
|
2022
Q2 | $1.54M | Buy |
39,116
+266
| +0.7% | +$7.89K | ﹤0.01% | 2567 |
|
|
2022
Q1 | $1.43M | Buy |
38,850
+4,426
| +13% | +$277K | ﹤0.01% | 2694 |
|
|
2021
Q4 | $3.37M | Hold |
34,424
| – | – | ﹤0.01% | 2451 |
|
|
2021
Q3 | $4.3M | Hold |
34,424
| – | – | ﹤0.01% | 2402 |
|
|
2021
Q2 | $4.32M | Hold |
34,424
| – | – | ﹤0.01% | 2373 |
|
|
2021
Q1 | $4.67M | Hold |
34,424
| – | – | ﹤0.01% | 2276 |
|
|
2020
Q4 | $3.13M | Sell |
34,424
-49,432
| -59% | -$4.29M | ﹤0.01% | 2298 |
|
|
2020
Q3 | $6.24M | Hold |
83,856
| – | – | ﹤0.01% | 1996 |
|
|
2020
Q2 | $7.14M | Buy |
+83,856
| New | +$7.6M | ﹤0.01% | 1931 |
|
|
2019
Q4 | – | Sell |
-17,941
| Closed | -$942K | – | 4199 |
|
|
2019
Q3 | $942K | Buy |
17,941
+852
| +5% | +$45.3K | ﹤0.01% | 2430 |
|
|
2019
Q2 | $918K | Buy |
17,089
+15,967
| +1,423% | +$1.09M | ﹤0.01% | 2463 |
|
|
2019
Q1 | $80K | Sell |
1,122
-10,380
| -90% | -$658K | ﹤0.01% | 2709 |
|
|
2018
Q4 | $918K | Buy |
11,502
+2,188
| +23% | +$499K | ﹤0.01% | 2408 |
|
|
2018
Q3 | $4.34M | Hold |
9,314
| – | – | ﹤0.01% | 2206 |
|
|
2018
Q2 | $3.7M | Sell |
9,314
-4,652
| -33% | -$1.65M | ﹤0.01% | 2219 |
|
|
2018
Q1 | $4.27M | Hold |
13,966
| – | – | ﹤0.01% | 2211 |
|
|
2017
Q4 | $4.11M | Buy |
13,966
+4,443
| +47% | +$1.94M | ﹤0.01% | 2209 |
|
|
2017
Q3 | $5.21M | Hold |
9,523
| – | – | ﹤0.01% | 2147 |
|
|
2017
Q2 | $5.67M | Hold |
9,523
| – | – | ﹤0.01% | 2133 |
|
|
2017
Q1 | $4.09M | Hold |
9,523
| – | – | ﹤0.01% | 2209 |
|
|
2016
Q4 | $4.9M | Hold |
9,523
| – | – | ﹤0.01% | 2183 |
|
|
2016
Q3 | $4.07M | Hold |
9,523
| – | – | ﹤0.01% | 2241 |
|
|
2016
Q2 | $4M | Buy |
+9,523
| New | +$4M | ﹤0.01% | 2236 |
|
Other funds holding RNAC
6CM
Fidelity Investments's RNAC Position: Q2 2026 in Review
Fidelity Investments reduced its Cartesian Therapeutics (RNAC) stake by 54% in Q2 2026, selling an estimated $3.2M and leaving 368,429 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.
Fidelity Investments first reported a position in RNAC in Q2 2016 and has held it in 39 quarters since. The position peaked at $46M in Q3 2024. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- Fidelity Investments held 368,429 shares of Cartesian Therapeutics worth $3.84M as of Q2 2026.
- Fidelity Investments sold 431,314 Cartesian Therapeutics shares in Q2 2026, an estimated $3.2M.
- Cartesian Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2522 holding.
- Fidelity Investments first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 39 quarters since.
- Fidelity Investments's Cartesian Therapeutics position peaked at $46M in Q3 2024.
- 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.